Table 3.

Frequency of pancreatobiliary complications in clinical trials with GLP-1 RA in people with obesity or T2D.

GLP-1 RA	Program	Refs	Target Patient	Dose	Administration	Cholelithiasis	AP
Semaglutide	SUSTAIN	9	T2D	1 mg	s.c. once weekly	0–2	0-<1
Semaglutide	STEP	10	Obesity *	2.4 mg	s.c. once weekly	<1–3	0-<1
Semaglutide	PIONEER	11	T2D	14 mg	p.o. QD	0-<1	0-<1
Liraglutide	LEAD	12	T2D	1.8 mg	s.c. QD	0	0-<1
Liraglutide	SCALE	13	Obesity *	3 mg	s.c. QD	<1–1	0-<1
Dulaglutide	AWARD	14	T2D	1.5 mg	s.c. once weekly	0	<1
Exenatide	DURATION	15	T2D	2 mg	s.c. once weekly	0-<1	0-<1
Exenatide	—	16	T2D	10 µg	s.c. BID	0	0
Lixisenatide	GETGOAL	17	T2D	20 µg	s.c. QD	0	0

Results are expressed as percentages of patients from the treatment cohort who had the complication at least once during the period of the study. Values correspond to the minimum and maximum values reported when considering all the studies of the program. * One out of 6 studies recruited people with obesity and T2D as well. AP, acute pancreatitis; BID, twice a day; GI AEs, gastrointestinal adverse events; GLP-1 RA, GLP-1 receptor agonist; n.r., not reported; p.o., oral; Refs, references; s.c., subcutaneous; QD, once a day; T2D, diabetes mellitus type 2.